Species | Brain Region | Receptor Type | Drugs | Release-Increasing Concentration | Comment | References |
---|---|---|---|---|---|---|
Rat | Striatum | 5-HT | 4 × 10–11–4 × 10–9 M | In vivo microdialysis in anesthetized (with chloral hydrate) rats; pindolol (4 nmol/40 μl fraction) inhibited the 5-HT (0.4 nmol/40 μl fraction)-evoked increase in DA release | Benloucif and Galloway (1991) | |
mCPP | 4 × 10–10–4 × 10–8 M | |||||
TFMPP | 10–8–1.6 × 10–7 M | |||||
RU 24969 | 2 × 10–9 M | |||||
8-OH-DPAT | 2 × 10–9 M | |||||
Fenfluramine | 4 × 10–10–4 × 10–8 M | |||||
Rat | Striatum | TFMPP | 3–30 mg/kg | Ex vivo determination of 3-MTa as an indirect parameter for DA release in vivo with HPLC in homogenates of striatal tissue; 3-MT, TFMPP, or ritanserin applied by s.c. injection; ritanserin without effect | Nissbrandt et al. (1992) | |
Rat | Striatum | 5-HT1, 5-HT3 | 5-HT | 10–5–10–4 M | In vivo microdialysis in anesthetized rats; drugs applied by probe perfusion; pindolol (4 nmol/40 μl fraction) reduced the effect of RU 24969 (2 nmol/40 μl fraction); ICS 205,930 (4 nmol/40 μl fraction), and MDL 72222 (4 nmol/40 μl fraction) reduced the facilitatory effect of 5-HT; ritanserin without effect; involvement of 5-HT1 and 5-HT3, but not of 5-HT2, receptors suggested | Benloucif et al. (1993) |
RU 24969 | 3 × 10–5–3 × 10–4 M | |||||
5-MeOT | 3 × 10–4–3 × 10–3 M | |||||
8-OH-DPAT | 10–4–3 × 10–3 M | |||||
DOI | 3 × 10–4–3 × 10–3 M | |||||
Rat | Striatum | 5-HT | 10–6–10–5 M DA, DOPAC, and HVA increased | In vivo microdialysis in freely moving rats; 5-HT, 5-HIAA, DA, DOPAC, and HVA determined in the dialysate; drugs; 5,7-DHT pretreatment abolished the effect of the 5-HT uptake inhibitor alaproclate on dialysate levels of DA | Yadid et al. (1994) | |
Alaproclatee | ||||||
CGS 12066B | 4 × 10–4 M | |||||
10–6 M | ||||||
Rat | Medial prefrontal cortex | 5-HT2A | MDL 100,907 | 0.1–1 mg/kg s.c. or 10–6 M directly i.c.v. | In vivo microdialysis in freely moving rats; ritanserin (2.5 mg/kg s.c.) without effect; 5-HT2A receptors probably involved, but location on interneurons probable | Schmidt and Fadayel (1995) |
Mouse 5-HT1B ko | Dorsal striatum | CP-93,129 | 5 × 10–5 M: 5-fold increase | In vivo microdialysis in anesthetized mice; CP-93,129 increased DA release in 5-HT1B ko and in wild-type mice | De Groote et al. (2003) |
3-MT, 3-methoxytryptamine (dopamine metabolite); HPLC, high-pressure liquid chromatography; 5-MeOT, 5-methoxytryptamine (5-HT4 agonist); DOPAC, 3,4-dihydroxyphenylacetic acid (dopamine metabolite); HVA, homovanillic acid (catecholamine metabolite); 5-HIAA, 5-hydroxyindoleacetic acid (5-HT metabolite); ko, knockout
↵ a Accumulation of the DA metabolite 3-MT formed by catechol-O-methyltransferase after inhibition of monoamine oxidase by pargyline was used as an indirect measure of dopamine release and metabolism in vivo
↵ b 5-HT reuptake blocker